# $\beta$ -(1 $\rightarrow$ 3,1 $\rightarrow$ 6)-D-GLUCANS IN DISEASE PREVENTION AND HEALTH PROMOTION – A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS

### Vlassopoulou M.<sup>1,2</sup>, Kyriacou A.<sup>2</sup>, Pletsa V.<sup>1</sup>, Zervakis G.I.<sup>3</sup>, Yannakoulia M.<sup>2</sup>

<sup>1</sup> Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

- <sup>2</sup> Department of Nutrition and Dietetics, Harokopio University, Athens, Greece
- <sup>3</sup> Laboratory of General and Agricultural Microbiology, Department of Crop Science, Agricultural University of Athens, Greece

## INTRODUCTION

- β-Glucans are categorized as dietary fibers due to their ability to reach the large intestine undigested and undergo fermentation by gut microbiota
- This heterogeneous group of polysaccharides exhibits a wide range of biological properties, as a result of their varying morphology
- >  $\beta$ -(1 $\rightarrow$ 3,1 $\rightarrow$ 6)-D-glucans is a form of  $\beta$ -glucans that is naturally found in the cell walls of yeast and higher fungi

**Purpose of review**: To assess the impact of consumption of

 $\beta$ -(1 $\rightarrow$ 3,1 $\rightarrow$ 6)-D-glucans on health outcomes

# **MATERIALS & METHODS**

Databases reviewed: PubMed, Cochrane Library, Web of Science

Inclusion criteria:

- ✓ Clinical trials with healthy individuals and/or patients
- ✓ Use of  $\beta$ -(1→3,1→6)-D-glucans (no other form of  $\beta$ -glucan)
- $\checkmark$  Full-text publication in English

Exclusion criteria:

- $\times$   $\;$  Lack of control group or randomization
- $\times$  Non-oral administration



Figure 1: Flow diagram (The PRISMA Group, 2009)



Aureobasidium pullulans

- <u>Immunomodulation</u>
- Strengthened immune defence
  => reduction of incidence and symptoms of
  - cold, flu and upper respiratory tract infections
- Alleviation of allergic symptoms



### Overweight adults

- 🖡 Body fat mass
- Abdominal circumference



### Cancer patients

- (Co-administration with chemotherapeutic drugs)
- Quality Of Life score enhancement



**Figure 2: 6-Glucan source.** Most of the trials used yeast-derived  $\beta$ -glucan. The daily dosage varied across studies from 2.5 mg to 1 g and was administered for 1 to 26 weeks.

# Ment

# Mental health

- Prolonged survival

- Improvement of mood state
- Amelioration of overall wellbeing

### CONCLUSIONS

Supplementation with  $\beta$ -(1 $\rightarrow$ 3,1 $\rightarrow$ 6)-D-glucans is well-tolerated and their health-promoting properties are manifested primarily through the potentiation of the immune system.

### PERSPECTIVES

Further investigation is required in order to unravel the molecular mechanisms of the aforementioned effects, as well as to establish the optimal administration parameters and source of extraction.

#### REFERENCES

Auinger 2013; Bergendiova et al., 2011; Bobovčák et al., 2010; Carpenter et al., 2013; Dharsono et al., 2018; Feldman et al., 2009; Fuller et al., 2012; Fuller et al., 2017; Gaullier et al., 2011; Graubau et al., 2012; Henao et al., 2018; Jesenak 2013; Jesenak 2014; Jippo et al., 2015; Jung et al., 2014; Kirmaz et al., 2005; Leentjens 2014; McFarlin et al., 2013; Meng et al., 2016; Mosikanon et al., 2017; Nakano et al., 1999; Ostadrahimi et al., 2014a; Ostadrahimi et al., 2014b; Richter et al., 2015; Santas et al., 2017; Strączkowski et al., 2018; Talbott & Talbott, 2009; Talbott & Talbott, 2010; Talbott & Talbott, 2012; Talbott et al., 2013; Vaclav et al., 2013; Yamada et al., 2007; Yenidogan et al., 2014

### ACKNOWLEDGEMENTS

This research has been co-financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE (project code: T1EDK-03404).







Με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης



ETOK





https://funglucan.hua.gr/ f FUNglucan @ @funglucan y @nglucan